TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01411267
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2/day IV on days 1 through 5.
Study: NCT04562792
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
Study: NCT00662688
Drug: daltéparine
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03348631
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01152450
Drug: Tiotropium 2.5 µg b.i.d
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
Study: NCT01152450
Drug: Tiotropium 5 µg q.d.
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
Study: NCT03331341
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03331341
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04390061
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Jak-1/3 inhibitor
Study: NCT04390061
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Therapy
Study: NCT02209831
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 days
Study: NCT02514603
Drug: Prexasertib
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01066403
Drug: Pergolide
Normalized name: Pergolide
DrugBank: Pergolide (DB01186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group.
Study: NCT02947750
Drug: 6R-BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
Study: NCT00544648
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
Study: NCT00544648
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
Study: NCT03470038
Drug: NGF
Normalized name: Hemoglobin Shuangfeng
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT00496223
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
Study: NCT00496223
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
Study: NCT01516229
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription of somatropin at the discretion of the physician
Study: NCT00551044
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 150mg once daily, oral administration, for 12 months
Study: NCT03143543
Drug: Group A Lorcaserin (10mg)
Normalized name: lorcaserin hydrochloride 10 MG
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg lorcaserin orally for 7 days
Study: NCT03143543
Drug: Group A2 Lorcaserin (20 mg)
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg lorcaserin orally for 7 days
Study: NCT01147588
Drug: lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg (2x30-mg capsule), once daily
Study: NCT01147588
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg (2x40-mg capsule), once daily
Study: NCT01147588
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg (1x40-mg capsule), once daily
Study: NCT01147588
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days
Study: NCT02563951
Drug: Kytril 1mg (IV injection)
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02563951
Drug: Kytril 1mg (Tablet)
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01366144
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03833596
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
Study: NCT01981486
Drug: PF-05180999 Tablets
Normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID modified-release tablets (20 to 240 mg BID)
Study: NCT04141410
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Levosimendan in cardiogenic shock during sepsis
Study: NCT01165684
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted.
Study: NCT01165684
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart added before each main meal. Doses individually adjusted.
Study: NCT01165684
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
Study: NCT01366144
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01366144
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00472550
Drug: esomeprazole 20 mg
Normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00299182
Drug: AMG 531
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Study: NCT02477566
Drug: Long-acting Triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
Study: NCT02477566
Drug: Short-acting Triptorelin
Normalized name: Short-acting sulfonamides
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
Study: NCT00299182
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
Study: NCT04138849
Drug: BBT-877 single dose
Normalized name: BBT-877
DrugBank: BBT-877 (DB18668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, single dose.
Study: NCT00299182
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
Study: NCT00299182
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
Study: NCT00299182
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
Study: NCT01841177
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Study: NCT02422524
Drug: PA-824
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
Study: NCT04167358
Drug: Linerixibat
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive linerixibat.
Study: NCT03719768
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
Study: NCT03047213
Drug: Sapanisertib
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00001258
Drug: Oxygen-15 Water
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03467191
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target BAC .08%
Study: NCT04225117
Drug: enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous (IV) infusion
Study: NCT04225117
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03738852
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard insulin regimen
Study: NCT00318552
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01849146
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01849146
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04477343
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allosteric inhibitor to human CXCR1 and CXCR2 receptor
Study: NCT04477343
Drug: Nivolumab Injectable Product
Normalized name: nivolumab Injectable Product
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: humanized monoclonal antibody to program cell death receptor 1 (PD1)
Study: NCT04252365
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given i.v.
Study: NCT04252365
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given i.v.
Study: NCT03714308
Drug: Ivt. Aflibercept (Eylea, BAY86-5321)
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment is applied according to routine clinical practice and independent of the study setting.
Study: NCT02008721
Drug: EGCG as putative neuroprotective agent
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
Study: NCT01593527
Drug: Triamcinelone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinelone acetonide 40 mg i.m.
Study: NCT00112489
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00112489
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01466803
Drug: Vorikonazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Study: NCT00394446
Drug: MPC-6827
Normalized name: GIVI-MPC
DrugBank: GIVI-MPC (DB17905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
Study: NCT01254071
Drug: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
Study: NCT02058472
Drug: G3041
Normalized name: Galsulfase
DrugBank: Galsulfase (DB01279)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01205828
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
Study: NCT01205828
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-888 40 mg BID PO Days 1-7 every 28 days
Study: NCT03341286
Drug: TK3
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tryptophan and thiamine as on oral supplement
Study: NCT00449410
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00449410
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02952729
Drug: XMT-1522
Normalized name: XMT-2056
DrugBank: XMT-2056 (DB18230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one intravenous dose administered in-clinic every 21 days
Study: NCT00656773
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
Study: NCT03410836
Drug: intravenous lidocaine (IVL)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
Study: NCT02867904
Drug: Methylprednisolone (40 mg depomedrol, 1ml, injection)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental Drug
Study: NCT04562610
Drug: All oral administration group
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
Study: NCT00194909
Drug: sildenafil (Viagra)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02867904
Drug: Marcaine (4ml 0.5%, injection)
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT01003886
Drug: Doxazosin mesylate GITS
Normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin mesylate GITS 4mg to 8mg once daily
Study: NCT00199485
Drug: Angelica Sinensis
Normalized name: ANGELICA SINENSIS ROOT
DrugBank: Angelica sinensis root (DB14336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angelica Sinensis / placebo
Study: NCT00096668
Drug: TOCOSOL(R) Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01518283
Drug: Cabazitaxel 10 mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
Study: NCT00786812
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01491295
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
Study: NCT01528813
Drug: Amorolfine lacquer
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
Study: NCT01458366
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.
Study: NCT01458366
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1
Study: NCT01458366
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase II: AUC 5 via IV on Day 2 of each cycle
Study: NCT01458366
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
Study: NCT04113109
Drug: Icatibant
Normalized name: Icatibant
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
Study: NCT04113109
Drug: Para-aminohippurate
Normalized name: para-aminohippurate
DrugBank: Aminohippuric acid (DB00345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
Study: NCT04113109
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
Study: NCT04189094
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
Study: NCT04189094
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Study: NCT04189094
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study: NCT00593138
Drug: dex-methylphenidate
DrugBank: Dexmethylphenidate (DB06701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
Study: NCT02039479
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium as Add on to every necessary treatment as usual
Study: NCT00597233
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes